Functional characterization of a novel class A carbapenemase CAE-1 in carbapenem-resistant Pseudomonas aeruginosa clinical isolates
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01362-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Jinhong Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Pseudomonas aeruginosa, beta-Lactamases, Carbapenems, Anti-Bacterial Agents. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Science and Technology Commission, National Natural Science Foundation of China.
Abstract (Originalsprache)
Two carbapenem-resistant Pseudomonas aeruginosa (CRPA) isolates were collected, which lacked known carbapenemases but produced a β-lactamase CAE-1. CAE-1 was recently found in Comamonas aquatica and conferred resistance to penicillins and cephalosporins. In this study, we aim to know whether CAE-1 was responsible for the carbapenem resistance in the CRPA isolates and its enzyme hydrolyzing characteristics. Both CRPA clinical isolates exhibited minimal inhibitory concentrations (MICs) of 8 µg/mL for imipenem and meropenem, with a positive result in the modified Hodge test for meropenem. The bla CAE-1 and bla KPC-2 were cloned and expressed in P. aeruginosa PAO1 and Escherichia coli DH5α, respectively. The bla CAE-1 -carrying PAO1 transformant also tested positive using the modified carbapenem inactivation method and was resistant to piperacillin-tazobactam, ticarcillin-clavulanate, and cefoperazone-sulbactam, but susceptible to ceftazidime-avibactam. Expression of bla CAE-1 in P. aeruginosa PAO1 elicited a 64- to 128-fold increase in MICs for piperacillin, ceftazidime, cefepime, and aztreonam, and an eightfold increase for meropenem, exhibiting a broader resistance profile than in E. coli DH5α. Steady-state kinetic assays showed that CAE-1 had catalytic efficiency against all β-lactams tested, with comparatively lower efficiency against three carbapenems relative to KPC-2, while demonstrating approximately equivalent efficiency for the other β-lactam antibiotics tested. Whole-genome sequencing revealed that bla CAE-1 was a class A β-lactamase and encoded on an integrative and conjugative element, which might facilitate its horizontal transfer. The class A β-lactamase CAE-1 is a carbapenemase posing a high risk for horizontal dissemination. Enhanced surveillance for bla CAE-1 -harboring isolates is needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
- Key Laboratory of Clinical Pharmacology of Antibiotics, National Health Commission of the People's Republic of China, Shanghai, China.
- Department of Laboratory Medicine, Huashan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Jinhong Chen, Zhewei Sun, Minggui Wang
Förderung
- Shanghai Municipal Science and Technology Commission
- National Natural Science Foundation of China
Zitieren
APA
Chen, J., Sun, Z., Su, J., Li, P., Xu, X., & Wang, M. (2026). Functional characterization of a novel class A carbapenemase CAE-1 in carbapenem-resistant Pseudomonas aeruginosa clinical isolates. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01362-25
Vancouver
Chen J, Sun Z, Su J, Li P, Xu X, Wang M. Functional characterization of a novel class A carbapenemase CAE-1 in carbapenem-resistant Pseudomonas aeruginosa clinical isolates. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01362-25
BibTeX
@article{Chen2026,
author = {Chen, Jinhong and Sun, Zhewei and Su, Jiachun and Li, Pei and Xu, Xiaogang and Wang, Minggui},
title = {Functional characterization of a novel class A carbapenemase CAE-1 in carbapenem-resistant Pseudomonas aeruginosa clinical isolates},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01362-25}
}
EUVIMED